 |
 |
 |
 |
| TECHNOLOGY PLATFORM |
 |
 |
 |
 |
 |
 |
Promising new Immunotherapies based on Human Chorionic Gonadotropin
CG Therapeutics, Inc. is a biotechnology company developing immunotherapies that target hCG, the pregnancy hormone that sometimes contributes to cancer malignancy. The company's goal is to be a leading immunotherapy company based on the following development programs:
Cancer Therapy - CG201, the company's lead product, is an injection that stimulates antibodies to block the pathological forms of hCG that help cancer cells grow and evade the immune system. CGT is also developing anti-hCG monoclonal antibodies for use in combination with CG201.
Immunocontraceptive - CG201 was originally created in collaboration with the World Health Organization as a low-cost contraceptive method for developing countries. CG201 is now approved for a Phase I clinical trial in Sweden. A single injection can protect against pregnancy for up to one year, and protection is reversible after that.
Immunosuppressant - CGT's anti-inflammatory program is developing hCG-based products for treating arthritis, psoriasis, tissue transplant rejection, and other autoimmune and inflammatory conditions.
